Partnership for Research on Ebola VACcinations (PREVAC)

Trial Profile

Partnership for Research on Ebola VACcinations (PREVAC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Pharmacodynamics
  • Acronyms PREVAC
  • Most Recent Events

    • 12 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 13 Mar 2017 Planned number of patients changed from 4900 to 5500.
    • 13 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top